Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of ...

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders,

Related Keywords

New York ,United States ,Florida ,Miami Beach ,Toronto ,Ontario ,Canada ,American ,Roger Mcintyre ,Jeffrey Cummings ,Harryl Smith ,Andrew Muzyk ,Darren Opland ,David Gozal ,Mark Jacobson ,Department Of Brain Health ,Axsome Therapeutics Inc ,Drug Administration ,University Of Toronto ,Nasdaq ,Corporate Communications ,Development Program ,Department Of Child Health ,American Society Of Clinical Psychopharmacology ,World Trade Center ,University Of Missouri ,Clinical Psychopharmacology ,Annual Meeting ,Improving Anhedonia ,Interest Activity Symptoms ,Associated Improvements ,Major Depressive ,Associate Professor ,Medical Education ,Clinical Profile ,Treating Alzheimer ,Disease Agitation ,Results From The Phase ,Vice Chair ,Solriamfetol Improves Cognitive Performance ,Preclinical Models ,Sleep Apnea ,Randomized Placebo Controlled Study ,Sleep Apnea Participants ,Endowed Chair ,Child Health ,Breakthrough Therapy ,Prescribing Information ,Boxed Warning ,Axsome Therapeutics ,